<DOC>
	<DOCNO>NCT00360360</DOCNO>
	<brief_summary>We evaluate feasibility , toxicity , effectiveness combination chemotherapy ( paclitaxel/carboplatin ) plus combination target therapy ( bevacizumab/erlotinib ) first line treatment patient carcinoma unknown primary site . There limited experience either bevacizumab erlotinib treatment cancer unknown site give heterogeneous nature tumor , likely inhibition angiogenesis pathways and/or EGFR pathway effective strategy least proportion .</brief_summary>
	<brief_title>Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib First Line Treatment Carcinoma Unknown Primary Site</brief_title>
	<detailed_description>All eligible patient receive : - Bevacizumab 15mg/kg IV infusion , Day 1 - Paclitaxel 175mg/m2 , 1-3 hour IV infusion , Day 1 - Carboplatin AUC 6.0 IV Day 1 - Erlotinib 150 mg mouth daily The regimen repeat every 21 day total 4 course . Patients initially evaluate response complete 2 course ( 6 week ) treatment . Patients objective tumor response stable disease continue treatment another 2 course . Patients re-evaluated 4 course objective tumor response stable disease stop chemotherapy paclitaxel/carboplatin continue treatment bevacizumab/erlotinib tumor progression document maximum 12 month . During treatment bevacizumab/erlotinib response evaluate every 12 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Biopsy proven metastatic carcinoma follow light microscopic histology : adenocarcinoma , poorly differentiate carcinoma ( must immunoperoxidase stain rule lymphoma , neuroendocrine carcinoma ) , poorly differentiate squamous carcinoma . ECOG performance status 01 No previous treatment systemic therapy Adequate kidney , liver bone marrow function Be able understand nature study give write informed consent The follow specific syndrome : Neuroendocrine carcinoma Women adenocarcinoma isolate axillary lymph node Women adenocarcinoma isolate peritoneal involvement Carcinoma involve one site resectable tumor site Squamous carcinoma limit cervical , supraclavicular , inguinal lymph node Uncontrolled brain metastasis patient meningeal involvement Women pregnant lactate Clinically significant cardiovascular disease History myocardial infarction stroke within 6 month Clinical history hemoptysis hematemesis Patients PEG tube Gtubes Proteinuria History bleed diathesis coagulopathy Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Neoplasm , Unknown Primary</keyword>
</DOC>